thiotepa has been researched along with Nervous System Disorders in 7 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of breast cancer meningeal carcinomatosis (MC) relies on intrathecal chemotherapy." | 5.39 | Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. ( Bidard, FC; Comte, A; Cottu, PH; Dieras, V; Dorval, T; Guilhaume, MN; Jdid, W; Kriegel, I; Mignot, L; Pierga, JY; Piperno-Neumann, S, 2013) |
| "Treatment of breast cancer meningeal carcinomatosis (MC) relies on intrathecal chemotherapy." | 1.39 | Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. ( Bidard, FC; Comte, A; Cottu, PH; Dieras, V; Dorval, T; Guilhaume, MN; Jdid, W; Kriegel, I; Mignot, L; Pierga, JY; Piperno-Neumann, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Comte, A | 1 |
| Jdid, W | 1 |
| Guilhaume, MN | 1 |
| Kriegel, I | 1 |
| Piperno-Neumann, S | 1 |
| Dieras, V | 1 |
| Dorval, T | 1 |
| Pierga, JY | 1 |
| Cottu, PH | 1 |
| Mignot, L | 1 |
| Bidard, FC | 1 |
| Vahdat, LT | 1 |
| Papadopoulos, K | 1 |
| Balmaceda, C | 1 |
| McGovern, T | 1 |
| Dunleavy, J | 1 |
| Kaufman, E | 1 |
| Fung, B | 1 |
| Garrett, T | 1 |
| Savage, D | 1 |
| Tiersten, A | 1 |
| Ayello, J | 1 |
| Bagiella, E | 1 |
| Heitjan, D | 1 |
| Antman, K | 1 |
| Hesdorffer, C | 1 |
| Papadakis, V | 1 |
| Dunkel, IJ | 1 |
| Cramer, LD | 1 |
| Kramer, E | 1 |
| Papadopoulos, E | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Willoughby, M | 1 |
| Baker, D | 1 |
| Garvin, J | 1 |
| Strandjord, S | 1 |
| Coccia, P | 1 |
| Kaplan, AM | 1 |
| Klemperer, M | 1 |
| Finlay, JL | 1 |
| Soussain, C | 1 |
| Suzan, F | 1 |
| Hoang-Xuan, K | 1 |
| Cassoux, N | 1 |
| Levy, V | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Leblond, V | 1 |
| Gutin, PH | 1 |
| Levi, JA | 1 |
| Wiernik, PH | 1 |
| Walker, MD | 1 |
| MartÃn Algarra, S | 1 |
| Henriquez, I | 1 |
| Rebollo, J | 1 |
| Artieda, J | 1 |
| Skeel, RT | 1 |
| Andersen, JW | 1 |
| Tormey, DC | 1 |
| Benson, AB | 1 |
| Asbury, RF | 1 |
| Falkson, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
3 trials available for thiotepa and Nervous System Disorders
| Article | Year |
|---|---|
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1998 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study.
Topics: Clinical Trials as Topic; Drug Evaluation; Hematologic Diseases; Humans; Injections, Spinal; Meninge | 1977 |
4 other studies available for thiotepa and Nervous System Disorders
| Article | Year |
|---|---|
Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2013 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2000 |
Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Axons; Central Nervous System Neo | 1990 |
Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1989 |